Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Bioniche Obtains Exclusive U.S. Rights to Equine Reproductive Product from CreoSalus

November 30, 2010

BELLEVILLE, ON, Nov. 30 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology
driven Canadian biopharmaceutical company, today announced that it has
signed an agreement with Thorn BioScience LLC, a subsidiary of
CreoSalus, Inc. The agreement provides exclusive rights to Bioniche to
market and distribute CreoSalus’ SucroMate(TM )Equine product in the U.S., with a first right of negotiation to expand
the territory.

SucroMate(TM) Equine was just registered in the U.S. by the U.S. Food and Drug
Administration (FDA), one of only 8 new FDA-approved animal health
drugs in 2010. It is a controlled release injectable of deslorelin
acetate, used to time ovulation in horses and increasing the likelihood
of conception during breeding. This is particularly valuable for
thoroughbred horses where natural breeding is utilized, and it is also
used in mares inseminated with fresh, cooled, and frozen semen.

“This product is a natural fit with the Bioniche Animal Health portfolio
of reproductive products for large animals, including horses,” said Jim
Phillips
, President of Bioniche Animal Health (global). “The Company
sells a portfolio of equine products in the U.S. market, and SucroMate;
(TM) Equine will be a welcome addition to our offerings to equine
veterinarians. SucroMate(TM) Equine particularly fits with our equine
mycobacterial cell wall product – Settle(TM) – a fast-acting, intrauterine or intravenous endometritis therapy for
broodmares.”

CreoSalus Co-Founder, Barry Simon, DVM, said, “Over a decade of research
and development has been devoted to develop a platform technology that
delivers peptides on a sustained release. SucroMate(TM) Equine is the first application of the technology. It delivers a
stable, sterile, and consistent dosage of deslorelin for mare
ovulation. FDA approval of SucroMate(TM) Equine provides veterinarians and horse owners with confidence in
breeding their mares. Horsemen will no longer need to rely on
compounded products that may not meet specifications or work properly.”

An estimated 250,000 to 300,000 mares are bred each year in the United
States
. Successful foaling is often a challenge due to mistimed
breeding or to other health complications such as endometritis.
Bioniche is pleased to offer registered products that help equine
veterinarians address these challenges. SucroMate(TM) Equine will be available for the start of the 2011 breeding season in
February, 2011.

About CreoSalus, Inc.

CreoSalus, Inc. is a privately held Louisville, Kentucky-based life
sciences company specializing in the development and manufacturing of
finished drugs, fine chemicals, and human medical devices. The
Company’s three operating businesses all relating to peptides are
Advanced ChemTech (fine chemicals), Occam Design (human medical
devices) and Thorn BioScience (finished drugs). Thorn BioScience’s
products include FDA-approved SucroMate(TM) Equine and SucroMate(TM) Porcine (under development) that regulate the ovulation in mares and
sows, respectively.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary products for
human and animal health markets worldwide. The fully-integrated company
employs 214 skilled personnel and has three operating divisions: Human
Health, Animal Health, and Food Safety. The Company’s primary goal is
to develop proprietary cancer therapies supported by revenues from
marketed products in human and animal health. Bioniche has been named
one of the Top 50 Best Small and Medium-Sized Employers in Canada for
2010. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
annual reporting.

SOURCE Bioniche Life Sciences Inc.


Source: newswire